
Gunner L. Hardy
Co-Founder, Drug Development Research
Gunner co-founded Contraview to measure how biotech science turns into value. He leads its work on exit prediction, clinical evidence and testing every model only on what was known at the time.
He trained in econometrics, Bayesian statistics and bioinformatics, including work that ran from RNA to genes to AlphaFold structure prediction and simulated protein interactions to annotate biosynthesis pathways.
He has invested in biotech and longevity at Conscience VC and Longevity Vision Fund, after banking and development finance at Bank of America Merrill Lynch, the EBRD and the World Bank. He holds master's degrees in biotechnology and in economics and finance.

